Real-World data reveals how immunotherapy combo performs against lung cancer
NCT ID NCT07526961
First seen Apr 19, 2026 · Last updated Jun 23, 2026 · Updated 9 times
Summary
This study looked back at medical records of 240 adults in Poland who received a combination of two immunotherapy drugs (nivolumab and ipilimumab) plus chemotherapy as their first treatment for advanced non-small cell lung cancer. The goal was to see how well the treatment worked in everyday hospital practice, not just in strict clinical trials. Researchers measured things like tumor shrinkage, how long patients lived, and what treatments they needed next.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Wielkopolska Center of Pulmonology and Thoracic Surgery of Eugenia and Janusz Zeyland
Poznan, Poland
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Nivolumab + Ipilimumab + Chemotherapy
What this could lead to
If successful, this could show how well this drug combination works outside of controlled trials, helping doctors make better treatment decisions for advanced lung cancer.
What could go wrong
This is a retrospective chart review, not a controlled experiment, so results may be influenced by missing data or patient selection. It cannot prove cause and effect.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.